ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Issue 6 (2nd May 2017)

• Record Type: Journal Article
• Authors: Bao, Lingjie; Wu, Jianfa; Dodson, Matthew; Rojo de la Vega, Elisa Montserrat; Ning, Yan; Zhang, Zhenbo; Yao, Ming; Zhang, Donna D.; Xu, Congjian; Yi, Xiaofang
• Is Part Of: Molecular carcinogenesis. Volume 56:Issue 6(2017)
• Page Start: 1543
• Page End: 1553
• Publication Date: 2017-05-02
• Subjects: ABCF2 -- chemoresistance -- cisplatin -- NRF2 -- ovarian cancer; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.22615
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract : Previously, we have demonstrated that NRF2 plays a key role in mediating cisplatin resistance in ovarian cancer. To further explore the mechanism underlying NRF2‐dependent cisplatin resistance, we stably overexpressed or knocked down NRF2 in parental and cisplatin‐resistant human ovarian cancer cells, respectively. These two pairs of stable cell lines were then subjected to microarray analysis, where we identified 18 putative NRF2 target genes. Among these genes, ABCF2, a cytosolic member of the ABC superfamily of transporters, has previously been reported to contribute to chemoresistance in clear cell ovarian cancer. A detailed analysis on ABCF2 revealed a functional antioxidant response element (ARE) in its promoter region, establishing ABCF2 as an NRF2 target gene. Next, we investigated the contribution of ABCF2 in NRF2‐mediated cisplatin resistance using our stable ovarian cancer cell lines. The NRF2‐overexpressing cell line, containing high levels of ABCF2, was more resistant to cisplatin‐induced apoptosis compared to its control cell line; whereas the NRF2 knockdown cell line with low levels of ABCF2, was more sensitive to cisplatin treatment than its control cell line. Furthermore, transient overexpression of ABCF2 in the parental cells decreased apoptosis and increased cell viability following cisplatin treatment. Conversely, knockdown of ABCF2 using specific siRNA notably increased apoptosis and decreased cell viability in cisplatin‐resistant cells treated with cisplatin. This data indicate that the novel NRF2 target gene, ABCF2, plays a critical role in cisplatin resistance in ovarian cancer, and that targeting ABCF2 may be a new strategy to improve chemotherapeutic efficiency.